(de-news.net) – Germany’s statutory health insurers have intensified pressure on political leaders to adopt more decisive measures in response to the continuing rise in pharmaceutical costs. Oliver Blatt, head of the GKV umbrella association, emphasized that governmental efforts to mitigate this upward trend had been marked by excessive caution, and he underscored that drug prices in Germany were second only to those in the United States on a global scale. He further argued that claims suggesting lower prices would drive manufacturers abroad were unsubstantiated, given that leading German pharmaceutical companies already maintain extensive production operations in countries such as China and India, demonstrating that global manufacturing footprints were largely independent of domestic price adjustments.
Blatt pointed out that expenditures on medications had reached 58.5 billion euros in the previous year, representing the second-largest cost category within the healthcare system after hospitals and exceeding spending on outpatient medical care. He noted that over the past twelve years, the cost of newly developed drugs had more than doubled, reflecting both innovation-driven pricing and market dynamics. Analysts have attributed these substantial increases in part to demographic pressures arising from an aging population, which has elevated demand for pharmaceutical products, and in part to prescribing patterns in which physicians increasingly favor higher-priced treatments within therapeutic classes.
Blatt also reaffirmed that the German pharmaceutical market was robustly funded, noting the rapid accessibility of new medications to patients: on average, newly approved drugs became available to all 75 million statutory insurees within just a few weeks of authorization. He rejected the argument that implementing price limits would exacerbate supply shortages, explaining that most temporary bottlenecks are typically mitigated by alternative medications and that higher prices do not inherently improve availability. Given the potential for a multibillion-euro deficit, the GKV-Spitzenverband reiterated its call for policymakers to integrate the pharmaceutical sector into broader cost-containment strategies, stressing that coordinated engagement was both feasible and necessary to maintain the financial health of Germany’s healthcare system.
The Social Association SoVD echoed the concerns raised by the insurers, with chair Michaela Engelmeier asserting that rising patient contributions could not be justified while pharmaceutical corporations continued to report multibillion-euro profits. Engelmeier called for urgent reform of the AMNOG framework to provide relief to both insurers and insured individuals, highlighting the necessity of rapid cost-benefit assessments of new pharmaceuticals prior to market approval as a means of preventing excessive initial pricing. Such measures were positioned as essential to ensuring that the financial burden of innovation did not unduly affect public health financing.
Health Minister Nina Warken (CDU) has established an expert commission tasked with delivering recommendations for healthcare savings by the end of March, aiming to address the financial sustainability of the system without restricting access.
Audio: TTSFree
